
Michael Nagler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9249487/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serological testing for SARSâ€CoVâ€2 antibodies in clinical practice: A comparative diagnostic accuracy study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2090-2103.	5.7	11
2	Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers. Journal of Translational Autoimmunity, 2022, 5, 100151.	4.0	0
3	Low COAT platelets are frequent in patients with bleeding disorders of unknown cause (BDUC) and can be enhanced byADDAVP. Journal of Thrombosis and Haemostasis, 2022, 20, 1271-1274.	3.8	5
4	Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. RMD Open, 2022, 8, e002166.	3.8	15
5	Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 883986.	2.4	7
6	Diagnostic accuracy of SARS-CoV-2 saliva antigen testing in a real-life clinical setting. International Journal of Infectious Diseases, 2022, 119, 38-40.	3.3	6
7	Heparin-induced Thrombocytopenia: Perioperative Diagnosis and Management. Anesthesiology, 2022, 136, 336-344.	2.5	6
8	Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study. Frontiers in Cardiovascular Medicine, 2022, 9, 817826.	2.4	10
9	Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study. Life, 2022, 12, 1027.	2.4	1
10	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale. Journal of Cardiovascular Translational Research, 2021, 14, 110-119.	2.4	7
11	How would we treat our own heparin-induced thrombocytopenia during cardiac surgery?. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1585-1593.	1.3	10
12	Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. British Journal of Clinical Pharmacology, 2021, 87, 1466-1474.	2.4	15
13	Andexanet Alfa–Induced Heparin Resistance: When Anticoagulation Really Remains Reversed. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 908-909.	1.3	16
14	Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103238.	4.4	14
15	Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial― Circulation, 2021, 143, e797-e798.	1.6	0
16	Immunoadsorption for the Treatment of Acquired Hemophilia: New Observational Data, Systematic Review, and Meta-Analysis. Transfusion Medicine Reviews, 2021, 35, 125-134.	2.0	6
17	Falls in ED patients: do elderly patients on direct oral anticoagulants bleed less than those on vitamin K antagonists?. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2021, 29, 56.	2.6	2
18	Predicting Recurrent Venous Thromboembolism in Patients With Deep-Vein Thrombosis: Development and Internal Validation of a Potential New Prediction Model (Continu-8). Frontiers in Cardiovascular Medicine, 2021, 8, 655226.	2.4	7

#	Article	IF	CITATIONS
19	Comparative effectiveness and safety of anticoagulants for the treatment of heparinâ€induced thrombocytopenia. American Journal of Hematology, 2021, 96, 805-815.	4.1	29
20	A universal antiâ€Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation. British Journal of Haematology, 2021, 193, 1203-1212.	2.5	24
21	Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland. , 2021, 41, .		Ο
22	A universal anti-Xa assay for the determination of rivaroxaban, apixaban, and edoxaban drug levels: development, diagnostic accuracy, and external validation. , 2021, 41, .		0
23	Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm® for the diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2021, 203, 22-26.	1.7	4
24	Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings. International Journal of Infectious Diseases, 2021, 109, 118-122.	3.3	82
25	Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements. Frontiers in Cardiovascular Medicine, 2021, 8, 717939.	2.4	10
26	Changing Perspectives of Local Therapists Eight Years after the Implementation of an Occupational Therapy Service in a Unique Himalayan Cross-Cultural Setting. Occupational Therapy International, 2021, 2021, 1-13.	0.7	0
27	Impaired kidney function at ED admission: a comparison of bleeding complications of patients with different oral anticoagulants. BMC Emergency Medicine, 2021, 21, 105.	1.9	1
28	Long-Term Survival After Venous Thromboembolism: A Prospective Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 749342.	2.4	5
29	Accuracy of serological testing for SARS oVâ€2 antibodies: First results of a large mixedâ€method evaluation study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 853-865.	5.7	34
30	Risk of Recurrence after Stopping Anticoagulants in Women with Combined Oral Contraceptive-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 776-776.	1.4	0
31	Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2020, 185, 27-30.	1.7	17
32	Rivaroxaban in patients with mechanical heart valves: A pilot study. Thrombosis Research, 2020, 186, 1-6.	1.7	20
33	System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings. Blood Coagulation and Fibrinolysis, 2020, 31, 459-468.	1.0	5
34	<p>Trends in Micronutrient Laboratory Testing in Switzerland: A 7-Year Retrospective Analysis of Healthcare Claims Data</p> . International Journal of General Medicine, 2020, Volume 13, 1341-1348.	1.8	9
35	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67
36	Utility of the Platelet Function Analyzer in Patients with Suspected Platelet Function Disorders: Diagnostic Accuracy Study. TH Open, 2020, 04, e427-e436.	1.4	3

#	Article	IF	CITATIONS
37	Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swiss Medical Weekly, 2020, 150, w20210.	1.6	9
38	Thromboprophylaxis and laboratory monitoring for in-hospital patients with Covid-19 - a Swiss consensus statement by the Working Party Hemostasis. Swiss Medical Weekly, 2020, 150, w20247.	1.6	77
39	Translating Laboratory Tests into Clinical Practice: A Conceptual Framework. Hamostaseologie, 2020, 40, 420-429.	1.9	4
40	Shorter Hospital Stay and Fewer Hospitalizations in Patients With Visible Hematuria on Direct Oral Anticoagulants Compared to on Vitamin K Antagonists. Urology, 2019, 132, 101-108.	1.0	1
41	Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 758-768.	2.3	47
42	Rapid Centrifugation in the Routine Hemostasis Laboratory. Thrombosis and Haemostasis, 2019, 119, 2025-2033.	3.4	9
43	Enhanced Thrombolysis by Ultrasound-Assisted Catheter-Directed Thrombolysis and Microbubbles in an In Vitro Model of Iliofemoral Deep Vein Thrombosis. Thrombosis and Haemostasis, 2019, 119, 1094-1101.	3.4	16
44	Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2019, 27, 48.	2.6	15
45	Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. Journal of Thrombosis and Haemostasis, 2019, 17, 1104-1112.	3.8	42
46	Orthotopic Liver Transplant in a Patient Anticoagulated With Rivaroxaban: A Case Report. A&A Practice, 2019, 13, 54-57.	0.4	2
47	Thromboelastometry as a diagnostic tool in mild bleeding disorders. European Journal of Anaesthesiology, 2019, 36, 457-465.	1.7	3
48	A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study. Journal of Thrombosis and Haemostasis, 2019, 17, 306-318.	3.8	9
49	Characteristics, treatment and outcome of bleeding after tooth extraction in patients on DOAC and phenprocoumon compared to non-anticoagulated patients—a retrospective study of emergency department consultations. Clinical Oral Investigations, 2019, 23, 2273-2278.	3.0	9
50	A Universal Anti-Xa Assay for the Determination of Rivaroxaban and Apixaban Plasma Concentrations: An In vitro Investigation and Evaluation Study in Real-life Clinical Practice. , 2019, 39, .		0
51	Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 299-309.	2.3	18
52	Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clinical Otolaryngology, 2018, 43, 103-108.	1.2	17
53	Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions. BMJ Open, 2018, 8, e022943.	1.9	11
54	Next generation viscoelasticity assays in cardiothoracic surgery: Feasibility of the TEG6s system. PLoS ONE, 2018, 13, e0209360.	2.5	18

#	Article	IF	CITATIONS
55	Association of anemia and hemoglobin decrease during acute stroke treatment with infarct growth and clinical outcome. PLoS ONE, 2018, 13, e0203535.	2.5	25
56	Short-term recovery pattern of plasma fibrinogen after cardiac surgery: A prospective observational study. PLoS ONE, 2018, 13, e0201647.	2.5	15
57	How I manage patients with anticoagulation-associated bleeding or urgent surgery. Swiss Medical Weekly, 2018, 148, w14598.	1.6	14
58	Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia. Expert Review of Molecular Diagnostics, 2017, 17, 419-426.	3.1	11
59	Accuracy and consistency of antiâ€Xa activity measurement for determination of rivaroxaban plasma levels. Journal of Thrombosis and Haemostasis, 2017, 15, 1576-1583.	3.8	21
60	Impact of a productâ€specific reference standard for the measurement of a <scp>PEG</scp> ylated <scp>rFVIII</scp> activity: the Swiss Multicentre Field Study. Haemophilia, 2017, 23, e335-e339.	2.1	20
61	Impact of rivaroxaban on point-of-care assays. Thrombosis Research, 2017, 153, 65-70.	1.7	26
62	Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. Journal of Thrombosis and Haemostasis, 2017, 15, 2165-2175.	3.8	6
63	Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review. Transfusion Medicine and Hemotherapy, 2017, 44, 78-83.	1.6	16
64	Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: Comparison of diagnostic accuracy, reproducibility, and costs in clinical practice. PLoS ONE, 2017, 12, e0178289.	2.5	14
65	Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2016, 116, 823-834.	3.4	41
66	Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice. Case Reports in Emergency Medicine, 2016, 2016, 1-3.	0.3	8
67	Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 2016, 127, 546-557.	1.4	112
68	Predictors of anticoagulation quality in 15Â834 patients performing patient selfâ€management of oral anticoagulation with vitamin K antagonists in realâ€life practice: a survey of the International Selfâ€Monitoring Association of Orally Anticoagulated Patients. British Journal of Haematology, 2016, 175, 677-685.	2.5	13
69	Thromboembolism in patients with congenital afibrinogenaemia. Thrombosis and Haemostasis, 2016, 116, 722-732.	3.4	32
70	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq0 (0 0 rgBT /0	Overlock 10 Ti

71	Patient selfâ€management of oral anticoagulation with vitamin K antagonists in everyday practice: comment on Jennings, <i>etÂal</i> British Journal of Haematology, 2014, 167:600–607. British Journal of Haematology, 2015, 169, 600-601.	2.5	3
72	Adherence to treatment with non-vitamin K antagonist anticoagulants: once- vs. twice-daily regimens. Europace, 2015, 17, 1316.1-1316.	1.7	1

#	Article	IF	CITATIONS
73	Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study. PLoS ONE, 2014, 9, e95761.	2.5	25
74	Consistency of thromboelastometry analysis under scrutiny: Results of a systematic evaluation within and between analysers. Thrombosis and Haemostasis, 2014, 111, 1161-1166.	3.4	20
75	Diagnostic value of the 4Ts score for heparin-induced thrombocytopenia in the critically ill. Journal of Critical Care, 2014, 29, 1126-1127.	2.2	5
76	Thromboelastometry changes in myeloproliferative neoplasms—surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons?. Annals of Hematology, 2014, 93, 1781-1782.	1.8	1
77	A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon. BMC Clinical Pathology, 2014, 14, 19.	1.8	35
78	Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation study. Thrombosis Journal, 2013, 11, 6.	2.1	16
79	Impact of changes in haematocrit level and platelet count on thromboelastometry parameters. Thrombosis Research, 2013, 131, 249-253.	1.7	36
80	Accuracy of the pointâ€of are coagulometer CoaguChek XS in the hands of patients. Journal of Thrombosis and Haemostasis, 2013, 11, 197-199.	3.8	9
81	Fondaparinux – data on efficacy and safety in special situations. Thrombosis Research, 2012, 129, 407-417.	1.7	75
82	Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2012, 10, 151-152.	3.8	33
83	Retrospective adjustment of self-assessed medical competencies - noteworthy in the evaluation of postgraduate practical training courses. GMS Zeitschrift Für Medizinische Ausbildung, 2012, 29, Doc45.	1.2	13
84	Leeching as a substitute for phlebotomy. British Journal of Haematology, 2011, 153, 420-420.	2.5	0
85	Long-term anticoagulation with fondaparinux in a patient with a mechanical heart valve. Annals of Hematology, 2011, 90, 1225-1226.	1.8	9
86	Iron Chelation with Deferasirox in Two Patients with HFE Hemochromatosis and Chronic Anemia. Acta Haematologica, 2011, 126, 119-121.	1.4	6
87	Severe Hyperkalemia and Bilateral Adrenal Metastasis. Journal of Oncology, 2009, 2009, 1-2.	1.3	4